Abstract
Accumulating evidence implicates a failure of myelin-reactive immune cells to undergo apoptosis in the pathological events contributing to multiple sclerosis (MS). We have recently demonstrated that members of the inhibitor of apoptosis (IAP) family of antiapoptotic genes are elevated in peripheral blood immune cells (monocytes, T cells) of patients with aggressive forms of MS (secondary progressive) or those with relapsing-remitting MS suffering a disease replase. These findings suggest that the IAPs may be novel diagnostic markers for distinguishing subtypes of MS. Moreover, antisense-mediated knockdown of the IAP family member known as Xlinked IAP (XIAP) reverses paralysis in an animal model of MS suggesting that treatments targeting XIAP, and perhaps other IAPs, may have utility in the treatment of MS.
Current Drug Discovery Technologies
Title: Targeting Apoptosis to Treat Multiple Sclerosis
Volume: 5 Issue: 1
Author(s): George S. Robertson, Andrea L.O. Hebb, Craig S. Moore and Virender Bhan
Affiliation:
Abstract: Accumulating evidence implicates a failure of myelin-reactive immune cells to undergo apoptosis in the pathological events contributing to multiple sclerosis (MS). We have recently demonstrated that members of the inhibitor of apoptosis (IAP) family of antiapoptotic genes are elevated in peripheral blood immune cells (monocytes, T cells) of patients with aggressive forms of MS (secondary progressive) or those with relapsing-remitting MS suffering a disease replase. These findings suggest that the IAPs may be novel diagnostic markers for distinguishing subtypes of MS. Moreover, antisense-mediated knockdown of the IAP family member known as Xlinked IAP (XIAP) reverses paralysis in an animal model of MS suggesting that treatments targeting XIAP, and perhaps other IAPs, may have utility in the treatment of MS.
Export Options
About this article
Cite this article as:
Robertson S. George, Hebb L.O. Andrea, Moore S. Craig and Bhan Virender, Targeting Apoptosis to Treat Multiple Sclerosis, Current Drug Discovery Technologies 2008; 5 (1) . https://dx.doi.org/10.2174/157016308783769432
DOI https://dx.doi.org/10.2174/157016308783769432 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complementary Peptide Epitopes and Antiidiotypic Antibodies in Autoimmunity
Protein & Peptide Letters TNF and TNF Receptors in TRAPS
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Comparative Genomics for the Investigation of Autoimmune Diseases
Current Pharmaceutical Design Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Emerging Role of Regulatory T Cells in Gene Transfer
Current Gene Therapy Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Current Pharmaceutical Design The Effects of Tamoxifen on Immunity
Current Medicinal Chemistry Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia
Current Neurovascular Research Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses
Current Drug Targets CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage
Current Neuropharmacology Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy